Structure-based modification of ortho-amidophenylaminopyrimidines as a novel mutant EGFR inhibitor against resistant non-small cell lung cancer

•Novel ortho-amidophenylaminopyrimidines as potential mutant EGFR inhibitors.•Ⅱd displayed strong inhibitory potency against EGFRL858R/ T790M/C797S and EGFRT790M/L858R kinases.•Ⅱd suppressed Ba/F3-EGFRL858R/T790M/C797S and H1975-EGFRL858R/T790M cells at nanomolar.•Ⅱd induced apoptosis in the resistant H1975 cells in a concentration-dependent manner.•Ⅱd suppressed phosphorylation of the EGFR and the downstream signaling ERK1/2 level in NSCLC cells.